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METHODS

Subjects
Six healthy human volunteers of normal weight [body mass index (BMI): 25.5 Ϯ 1.4 kg/m 2 ] (Table 1) , five abdominally fat obese patients (BMI 35.0 Ϯ 0.7 kg/m 2 and height/hip ratio Ͼ1), and three type 2 diabetic patients (Hb A1c Ͼ7%, BMI 35.0 Ϯ 3.0 kg/m 2 ) participated in this protocol. These patients represented a wide range of insulin sensitivity. Their clinical and biochemical parameters are shown in Table 1. These 14 subjects (7 females and 7 males, 47.9 Ϯ 8.3 yr old) were divided into two groups according to their insulin sensitivity. The IS group consisted of six volunteers (subjects 1-6) with normal insulin sensitivity. Eight insulin-resistant volunteers (subjects [7] [8] [9] [10] [11] [12] [13] [14] formed the IR group. The subjects were considered to be insulin resistant when the glucose consumption required for maintaining baseline blood glucose during a euglycemic clamp was Ͻ7.5 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 (6). The subjects had no acute pathology and were not under any medication. The experimental protocol was approved by the Ethics Committee of the University Hospital of Nantes (France).
Experimental Design
To avoid exogenous acetate production, a low-fiber diet (Ͻ5 g/day) was consumed by the volunteers for 3 days before the protocol began. The study was conducted after a 12-h overnight fast. On the morning of the experiment, two short polyethylene catheters (20 gauge; Vigon, Paris, France) were inserted into the antecubital vein for tracer infusion and on the wrist of the second arm to sample venous blood.
A primed constant infusion technique with the use of [l- 13 for 3 h. After 3 h of infusion, a hot clamp was started to obtain insulin concentration at Ϸ100 U/l (6). During the clamp, the glucose tracer rate was adjusted to the glucose infusion rate (ml/h) to maintain the glycemia between 4.9 and 5.5 mmol/l. Arterialized blood samples were collected at Ϫ180, Ϫ60, Ϫ45, Ϫ30, Ϫ20, Ϫ10, 0, 60, 120, 150, 160, 170, and 180 min ( Fig. 1 ). Respiratory gas exchanges were measured with the use of indirect calorimetry (Deltatrac, Helsinki, Finland) throughout the study. Expired breath gases were sampled before and after each blood sample.
Sampling Procedures and Gas Chromatograph-Mass Spectrometer Analysis
Acetate analysis. Measurement of plasma acetate enrichment was performed as previous described (14) . Briefly, an internal standard (24 l of [ 2 H3]acetate, 2.35 mmol/l) was added to 500 l of plasma sample to measure plasma acetate concentration. Plasma samples were deproteinized with 10 mg of sulfosalicylic acid (Sigma, St. Quentin Fallavier, France) and centrifuged at 2,200 g for 30 min. The supernatants were transferred into a glass tube and acidified by the addition of 30 l of HCl (10 mol/l) (Fluka, Bushs, Switzerland). Acetate and standards were extracted from plasma into 3 ml of diethyl ether (Fluka) by being vortexed for 15 min. The samples were centrifuged for 15 min at 1,200 g, and 8 l of tert-butyldimethylsilyl imidazole (Fluka) were added to the separated organic phase. The tert-butyldimethylsilyl derivatives were heated at 60°C for 30 min and then cooled and evaporated to 500 l.
Two microliters of acetate were injected into a split/splitless injector (splitless mode) into a gas chromatograph (GC; model 5890A, Hewlett-Packard, Palo Alto, CA) with the use of a 30 m ϫ 0.25 mm capillary column (model DB1, J/W Scientific, Folsom, CA) and connected with a quadrupole mass spectrometer (MS; model 5971A, Hewlett-Packard). The injector temperature and the transfer line between GC and MS were 250°C and 290°C, respectively. The temperature program started at 50°C and ramped to 85°C at 5°C/min, then up to 250°C at 50°C/min, followed by 1 min at 250°C. Electron impact ionization was operated with an electron energy rate of 70 eV. Selected ion monitoring mode of M-[C-(CH 3)3], corresponding to ions at mass-to-charge ratios (m/z) 117, 118, and 120, was used to measure acetate enrichment and concentration. Calibration curve for isotopic enrichments was prepared in the range of 0% to 20% for [l-
13 C]acetate. Concentration calibration levels were obtained from baseline to 390 mol/l of acetate. Glucose analysis. Fifty microliters of plasma samples were deproteinized with 300 l of acetone, vortexed, and centrifuged at 2,200 g for 15 min. The supernatants were dried under nitrogen vacuum (10) . The samples were derivatized with a mixture of 50 l of acetic anhydride and 50 l of pyridine (Sigma), at 80°C for 1 h, evaporated, and diluted in 1 ml of ethyl acetate (19) .
One microliter of a penta-acetate derivative was injected in the GC-MS system described above. The temperature program started at 80°C and ramped to 250°C at 30°C/min, followed by 3 min at 250°C. Electron impact ionization and selected ion monitoring mode were used on ions with m/z 98 and 100. Calibration curve was obtained from known isotopic enrichment solutions prepared in ethyl acetate ranging from 0% to 10% enrichment for [6,6- 2 H2]glucose. CO2 analysis. CO2 production (V CO2) was determined by indirect calorimetry and isotopic enrichment of expired CO2 was measured by GC-IRMS (Breathmat Plus, ThermoFinnigan, Bremen, Germany) with the use of a packed steel column (3 m Hayes Sep-D). A laboratory CO 2 standard calibration against the international P Belemnite (PDB) carbonate was used as a reference. The data were obtained in ␦ 13 C (in ‰).
Calculation Methods
Acetate. The rate of total appearance of acetate (Ra) was calculated according to the equations for steady state as follows
where i was the infusion rate (in mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ), Et and Ep were, respectively, the isotopic enrichment of the tracer ([l-
13 C]acetate), and the plasma at plateau given as mole percent excess (MPE).
Extracellular pool (mol/kg) was C ⅐ V d, where Vd is the distribution volume of acetate (0.2 l/kg) (12) .
Glucose. Before the hot clamp treatment was started, the [6,6-2 H2]glucose infusion was constant for 3 h. Therefore, the glucose Ra was calculated according to the equation used for acetate.
During the hot clamp treatment, the glucose R a was calculated with the Steele equation for nonsteady state, as follows
where F was the infusion flow of the tracer (in mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ), p was the pool fraction (0.65), V was the distribution volume of glucose (0.2 l/kg), G was the plasma concentration of glucose at time t (in g/l), and E p was the plasma isotopic enrichment of glucose at time t. 
Values are means Ϯ SE. IS, normal insulin sensitivity; IR, insulin resistance; BMI, body mass index; FBG, fasting blood glucose. where ECO2 was the isotopic enrichment of expired CO2 in APE, V CO2 was the expired rate of CO2 (mol/min), C was the recovery coefficient (0.78) for [l- 13 C]acetate in the postabsorptive state (20) , and M was the weight of the volunteer.
The percent oxidized (%Ox) was determined as
where Rd was the rate of disappearance of acetate. The percentage of V CO2 from oxidation of acetate (%V CO2) was
The acetate energy contribution (Cea, in %) was calculated with the equation as below
where Ea was the energy derived from acetate (1 mol of oxidized acetate ϭ 879 kJ) (5), and Et was the total energy (in kJ/min).
Statistical Analysis
Data are reported as means Ϯ SE unless otherwise stated. Correlation studies were realized among acetate rate, glucose rate, and insulin sensitivity. Statistical analysis was performed with the use of Instat Statistical software (GraphPad, San Diego, SA). Student's t-test was used to compare clinical and kinetic data of the subjects. Correlation analyses were performed with the use of Spearman's coefficient analysis. A two-tailed probability level of 0.05 was accepted as statistically significant.
RESULTS
At the end of the clamp study, all the IS subjects had a glucose consumption Ͼ7.5 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 and was 9.6 Ϯ 1.1 for the IS group vs. 4.9 Ϯ 0.5 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
for the IR group (P Ͻ 0.01) ( Table 2 ). In the IR group, BMI and the height/hip ratio were significantly higher for the IR group compared with the IS group: 35.0 Ϯ 1.1 versus 25.6 Ϯ 1.2 kg/m 2 (P Ͻ 0.01) and 1.0 Ϯ 0.01 versus 0.9 Ϯ 0.02 (P Ͻ 0.01). Glycemia and Hb A 1c were also higher in the IR group compared with the IS group: 7.4 Ϯ 1.2 mmol/l and 6.2 Ϯ 0.4% vs. 5.4 Ϯ 0.1 mmol/l and 5.4 Ϯ 0.1%, respectively (P ϭ 0.11 and 0.17). In the IS group, only one subject (subject 5) was obese, but all subjects showed a normal glucose tolerance (Table 1 ). In the IR group, all subjects were obese, three were diabetic (subjects [11] [12] [13] , and one showed glucose intolerance (subject 10). During and at the end of the protocol, mean glycemia and insulinemia were similar in the two groups: 5.2 Ϯ 0.05 mmol/l and 103.7 Ϯ 19.4 pmol/l in the IS group vs. 5.3 Ϯ 0.08 mmol/l and 143 Ϯ 11.3 pmol/l in the IR group (Table 2) . Free fatty acid plasma concentrations were higher in the IR group (0.6 Ϯ 0.04 mmol/l) than in the IS group (0.4 Ϯ 0.05 mmol/l) at baseline but decreased and became similar at the end of the clamp (IR: 0.07 Ϯ 0.01 mmol/l, IS: 0.06 Ϯ 0.01 mmol/l). No significant difference in baseline acetate concentrations was found between the two groups (Table 3) .
In the basal state, the constant infusion of [6,6-2 H 2 ]glucose led to similar glucose turnover in the two groups: 8.8 Ϯ 0.4 vs. 8.8 Ϯ 0.2 mmol ⅐ kg Ϫ1 ⅐ min Ϫ1 (P ϭ 0.6). During the hot clamp treatment, the glucose turn- (Table 3) .
The baseline acetate turnover rates were not significantly different among both groups (Fig. 2) . After the clamp, mean acetate turnover of the two groups increased and was higher in the IS group: 8.1 Ϯ 0.7 vs. 5.5 Ϯ 0.5 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 (P Ͻ 0.001) ( Table 3) . No significant correlation was found between acetate turnover or acetate concentration and glucose rate of infusion. No significant correlations were found between acetate turnover and glucose turnover or plasma free fatty acid concentration. The oxidation of acetate increased significantly with hyperinsulinemia in both groups and was higher in the IS group: 5.7 Ϯ 0.7
In basal conditions, the percentage of oxidized acetate calculated from acetate production was similar in both groups 67.7 Ϯ 3.4% (IS group) vs. 70.0 Ϯ 5.4% (IR group). After the clamp, it was 76.0 Ϯ 4.3% vs. 76.9 Ϯ 3.7%, respectively (Fig. 3) . The percentage of expired CO 2 from V CO 2 and C ea were also similar, ϳ3%, in both groups under basal conditions and increased significantly (V CO 2 70% for IS vs. 35% for IR; C ea 80% for IS vs. 70% for IR) after insulin administration (IS: P Ͻ 0.01, IR: P Ͻ 0.05).
DISCUSSION
In this study, the effect of insulin on acetate metabolism was analyzed. Under basal conditions, acetate turnover rate and plasma acetate concentration were similar in patients with normal or impaired insulin resistance. Acetate concentrations decreased with hyperinsulinemia in both groups but tended to be lower in the group with insulin resistance. The acetate turnover increased with insulin infusion, suggesting a concomitant increase in acetate production and utilization, but this effect was significantly lower in IR patients.
Akanji et al. (3) investigated changes in acetate concentration induced by a hyperinsulinemic euglycemic clamp in 13 nondiabetic individuals, including 7 obese patients, and in 9 diabetic patients. Acetate concentrations decreased in both groups during insulin administration. In the nondiabetic subjects, acetate concentrations returned to baseline during the second hour of the clamp. It was suggested that the lack of increase in acetate concentration of the diabetic patients was not related to insulin resistance, but rather to a difference in postreceptor glucose metabolism toward glycogenesis or glycolysis (1, 3) . In diabetic patients, decreased glycolysis may explain the decreased production of acetyl-CoA and therefore of acetate. Some studies (2, 8, 18) have already found a correlation between plasma acetate and glucose, thus supporting a conversion between acetate and glucose via acetylCoA.
Insulin induced an increase in acetate turnover and a decrease in acetate concentrations, but this effect was lower in patients with insulin resistance. On the one hand, the results indicated a reduction in acetate production in subjects with insulin resistance. On the other hand, insulin accelerated the catabolism of acetate, which is dependent on glucose availability (7). Consequently, decreased glucose uptake associated with insulin resistance may result in a decrease in acetate utilization. This permissive effect of glucose may have led to the increase in acetate flux seen during the hyperinsulinemic clamp because glucose turnover was increased, not only by the administration of insulin but also by the exogenous glucose supply needed to maintain blood glucose concentrations within the normal range. However, in our study, acetate turnover was correlated neither to glucose flux nor to fasting blood glucose concentrations, suggesting that acetate metabolism is sensitive to insulin rather than to glucose.
Insulin increased the rate of acetate catabolism, as shown by the increase in acetate metabolic clearance during the clamp. However, this effect was less marked in patients with insulin resistance. Mechanisms that may explain this decreased acetate catabolism associated with insulin resistance include decreased activity of the enzyme ACAS, decreased glucose utilization, and decreased acetate oxidation.
ACAS, which is involved in the conversion of acetate to acetyl-CoA, is sensitive to insulin action (13) . The decrease in acetate utilization that results from a decrease in ACAS activity is induced by insulin resistance. This mechanism has been recently documented in rats (17) . A decrease in acetate oxidation via acetylCoA may also explain the decrease in acetate utilization. In both groups, 65-68% of the acetate underwent oxidation. These percentages were similar to those found by our group in healthy volunteers (11) . Acetate oxidation was more marked in subjects with normal sensitivity to insulin, both under basal conditions and with insulin stimulation. However, the contribution of acetate to energy expenditures was similar in the two groups under basal conditions, ϳ3%, and increased twofold with insulin administration, indicating that acetate oxidation was proportional to acetate utilization. Insulin probably acts on the enzyme ACAS, which regulates acetate homeostasis and not oxidation. Insulin decreases the oxidation of free fatty acids and total lipids (9) . Thus acetate behaves differently compared with other fatty acids. Conversely, insulin increases glucose oxidation and nonoxidative glucose utilization (9) . Furthermore, the alteration in insulin effects associated with insulin resistance results in a decrease in glucose utilization. Our hypothesis supports the sensitivity of acetate to insulin action. Acetate metabolism is similar in this respect to glucose metabolism. Insulin resistance seems to contribute to the alteration in acetate metabolism associated with diabetes or obesity. Several authors have suggested that short-chain triglyceride solutions, such as triacetin, may be useful parenteral nutrients (4) . In case of insulin resistance, acetate should be used cautiously to avoid possible adverse effects as previously reported with acetate dialysis treatment (21) .
